Andrew Sloan

Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.

Somatic alterations in brain tumors.

Diagnosis and treatment of melanoma brain metastasis: a literature review.

Incidence patterns for primary malignant spinal cord gliomas: a Surveillance, Epidemiology, and End Results study.

Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.

Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study.

Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence.

A nomogram for individualized estimation of survival among patients with brain metastasis.

Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas.

Laminin alpha 2 enables glioblastoma stem cell growth.

Risk of subsequent cancer following a primary CNS tumor.

Aptamer identification of brain tumor-initiating cells.

Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake.

The somatic genomic landscape of glioblastoma.

Gene markers in brain tumors: what the epileptologist should know.

Molecular subtypes of glioblastoma are relevant to lower grade glioma.

Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer.

The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells.

Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010.

The role of cancer stem cells in glioblastoma.

Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth.

Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.

Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.

International Differences in Treatment and Clinical Outcomes for High Grade Glioma.

Extracranial metastasis of gliobastoma: Three illustrative cases and current review of the molecular pathology and management strategies.

Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma.

The role of emerging therapy in the management of patients with diffuse low grade glioma.

Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells.

Fluorescent-Guided Surgical Resection of Glioma with Targeted Molecular Imaging Agents: A Literature Review.

Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.

An IDH1-mutated primary gliosarcoma: case report.

Laser interstitial thermal therapy followed by minimal-access transsulcal resection for the treatment of large and difficult to access brain tumors.

Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination.

The ratio of HLA-DR and VNN2+ expression on CD14+ myeloid derived suppressor cells can distinguish glioblastoma from radiation necrosis patients.

Targeting glioma stem cells through combined BMI1 and EZH2 inhibition.